BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 32035193)

  • 1. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 6. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
    Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
    J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined GM-CSF treatment and M-CSF inhibition of tumor-associated macrophages induces dendritic cell-like signaling in vitro.
    Kitoh Y; Saio M; Gotoh N; Umemura N; Nonaka K; Bai J; Vizkeleti L; Torocsik D; Balazs M; Adany R; Takami T
    Int J Oncol; 2011 May; 38(5):1409-19. PubMed ID: 21373754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
    Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
    J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
    Holmgaard RB; Brachfeld A; Gasmi B; Jones DR; Mattar M; Doman T; Murphy M; Schaer D; Wolchok JD; Merghoub T
    Oncoimmunology; 2016 Jul; 5(7):e1151595. PubMed ID: 27622016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
    Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
    Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
    Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
    J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.
    Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y
    ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.
    Hu Y; Nie W; Lyu L; Zhang X; Wang W; Zhang Y; He S; Guo A; Liu F; Wang B; Qian Z; Gao X
    ACS Nano; 2024 Jan; 18(4):3295-3312. PubMed ID: 38252684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.
    Shu Y; Qin M; Song Y; Tang Q; Huang Y; Shen P; Lu Y
    Immunology; 2020 Aug; 160(4):345-356. PubMed ID: 32311768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
    Pyonteck SM; Akkari L; Schuhmacher AJ; Bowman RL; Sevenich L; Quail DF; Olson OC; Quick ML; Huse JT; Teijeiro V; Setty M; Leslie CS; Oei Y; Pedraza A; Zhang J; Brennan CW; Sutton JC; Holland EC; Daniel D; Joyce JA
    Nat Med; 2013 Oct; 19(10):1264-72. PubMed ID: 24056773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withholding of M-CSF Supplement Reprograms Macrophages to M2-Like via Endogenous
    Chen YC; Lai YS; Hsuuw YD; Chang KT
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
    Chen J; Tang Y; Qin D; Yu X; Tong H; Tang C; Tang Z
    J Transl Med; 2023 Dec; 21(1):923. PubMed ID: 38124204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.